文献速递肾移植血液净化与透析

透析与肾移植患者体外扩增自然调节性T细胞可用于自体细胞治疗

Ex vivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy.
PubMed 文献 · Kidney Int · 2018-01-01

该研究分析200例健康对照、透析的终末期肾病患者及肾移植后1至20年患者的外周血,用流式细胞术比较nTreg分化成熟。透析患者CD4+CD25highFoxP3+ nTreg频率升高,且透析、免疫抑制或既往急性排斥均不影响nTreg体内存活,体外扩增可获得高纯度自体nTreg产品。

要点

  • 透析患者nTreg频率升高且不影响扩增产品质量
  • 免疫抑制轻度影响nTreg成熟但不影响体内存活
  • 透析或肾移植患者可生成自体高纯度nTreg产品

核心结论

  • 透析或肾移植患者可生成自体高纯度nTreg产品,符合过继性nTreg治疗条件。

研究设计与样本

  • 研究纳入200例个体,包括健康对照、透析的终末期肾病患者及肾移植后1、5、10、15、20年患者。
  • 采用肝素化外周血,通过流式细胞术研究nTreg分化与成熟。

主要发现

  • 透析患者可检测到CD127表达的CD4+CD25highFoxP3+ nTreg频率增加。
  • 透析对体外扩增nTreg终产物的质量和治疗有效性无负面影响。
  • 免疫抑制轻度改变nTreg成熟,但透析、药物免疫抑制或既往急性排斥均未阻碍nTreg体内存活。

临床怎么用

  • 等待或已接受同种异体肾移植的患者可考虑自体nTreg过继治疗。
  • 该策略可能减少器官排斥发生率并降低长期免疫抑制需求。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Novel concepts employing autologous, ex vivo expanded natural regulatory T cells (nTreg) for adoptive transfer has potential to prevent organ rejection after kidney transplantation. However, the impact of dialysis and maintenance immunosuppression on the nTreg phenotype and peripheral survival is not well understood, but essential when assessing patient eligibility. The current study investigates regulatory T-cells in dialysis and kidney transplanted patients and the feasibility of generating a clinically useful nTreg product from these patients. Heparinized blood from 200 individuals including healthy controls, dialysis patients with end stage renal disease and patients 1, 5, 10, 15, 20 years after kidney transplantation were analyzed. Differentiation and maturation of nTregs were studied by flow cytometry in order to compare dialysis patients and kidney transplanted patients under maintenance immunosuppression to healthy controls. CD127 expressing CD4+CD25highFoxP3+ nTregs were detectable at increased frequencies in dialysis patients with no negative impact on the nTreg end product quality and therapeutic usefulness of the ex vivo expanded nTregs. Further, despite that immunosuppression mildly altered nTreg maturation, neither dialysis nor pharmacological immunosuppression or previous acute rejection episodes impeded nTreg survival in vivo. Accordingly, the generation of autologous, highly pure nTreg products is feasible and qualifies patients awaiting or having received allogenic kidney transplantation for adoptive nTreg therapy. Thus, our novel treatment approach may enable us to reduce the incidence of organ rejection and reduce the need of long-term immunosuppression.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Landwehr-Kenzel S, Zobel A, Hoffmann H, et al. Ex vivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy. Kidney Int. 2018. PMID: 29792274. doi:10.1016/j.kint.2018.01.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。